184 related articles for article (PubMed ID: 36692681)
1. Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan.
Ogura T; Inoue Y; Azuma A; Homma S; Kondoh Y; Tanaka K; Ochiai K; Sugiyama Y; Nukiwa T
Adv Ther; 2023 Apr; 40(4):1474-1493. PubMed ID: 36692681
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of nintedanib in Japanese patients with early-stage idiopathic pulmonary fibrosis: a study protocol for an observational study.
Sakamoto N; Hamada N; Okamoto M; Tobino K; Ichiyasu H; Ishii H; Ichikado K; Morimoto S; Hosogaya N; Mukae H
BMJ Open; 2021 Jun; 11(6):e047249. PubMed ID: 34187824
[TBL] [Abstract][Full Text] [Related]
3. Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis.
Ikeda S; Sekine A; Baba T; Katano T; Tabata E; Shintani R; Sadoyama S; Yamakawa H; Oda T; Okuda R; Kitamura H; Iwasawa T; Takemura T; Ogura T
BMC Pulm Med; 2019 Apr; 19(1):78. PubMed ID: 30975118
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan.
Hisata S; Bando M; Homma S; Kataoka K; Ogura T; Izumi S; Sakamoto S; Watanabe K; Saito Y; Shimizu Y; Kato M; Nishioka Y; Hara H; Waseda Y; Tanino Y; Yatera K; Hashimoto S; Mukae H; Inase N;
Respir Investig; 2021 Nov; 59(6):819-826. PubMed ID: 33994347
[TBL] [Abstract][Full Text] [Related]
5. Tolerability and safety of nintedanib in elderly patients with idiopathic pulmonary fibrosis.
Uchida Y; Ikeda S; Sekine A; Katano T; Tabata E; Oda T; Okuda R; Kitamura H; Baba T; Komatsu S; Ogura T
Respir Investig; 2021 Jan; 59(1):99-105. PubMed ID: 32891571
[TBL] [Abstract][Full Text] [Related]
6. All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis.
Ogura T; Azuma A; Inoue Y; Taniguchi H; Chida K; Bando M; Niimi Y; Kakutani S; Suga M; Sugiyama Y; Kudoh S; Nukiwa T
Respir Investig; 2015 Sep; 53(5):232-41. PubMed ID: 26344613
[TBL] [Abstract][Full Text] [Related]
7. Nintedanib in IPF: Post hoc Analysis of the Italian FIBRONET Observational Study.
Harari S; Pesci A; Albera C; Poletti V; Amici C; Crespi G; Campolo B; Vancheri C;
Respiration; 2022; 101(6):577-584. PubMed ID: 35078170
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities.
Glaspole I; Bonella F; Bargagli E; Glassberg MK; Caro F; Stansen W; Quaresma M; Orsatti L; Bendstrup E
Respir Res; 2021 Apr; 22(1):125. PubMed ID: 33902584
[TBL] [Abstract][Full Text] [Related]
9. Nintedanib can be used safely and effectively for idiopathic pulmonary fibrosis with predicted forced vital capacity ≤ 50%: A multi-center retrospective analysis.
Senoo S; Miyahara N; Taniguchi A; Oda N; Itano J; Higo H; Hara N; Watanabe H; Kano H; Suwaki T; Fuchimoto Y; Kajimoto K; Ichikawa H; Kudo K; Shibayama T; Tanimoto Y; Kuyama S; Kanehiro A; Maeda Y; Kiura K;
PLoS One; 2020; 15(8):e0236935. PubMed ID: 32853277
[TBL] [Abstract][Full Text] [Related]
10. Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
Brunnemer E; Wälscher J; Tenenbaum S; Hausmanns J; Schulze K; Seiter M; Heussel CP; Warth A; Herth FJF; Kreuter M
Respiration; 2018; 95(5):301-309. PubMed ID: 29490307
[TBL] [Abstract][Full Text] [Related]
11. Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSIS® randomized trials.
Azuma A; Taniguchi H; Inoue Y; Kondoh Y; Ogura T; Homma S; Fujimoto T; Sakamoto W; Sugiyama Y; Nukiwa T
Respirology; 2017 May; 22(4):750-757. PubMed ID: 27997064
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis: A Nationwide Post-Marketing Surveillance Study in Korean Patients.
Chung MP; Park MS; Oh IJ; Lee HB; Kim YW; Park JS; Uh ST; Kim YS; Jegal Y; Song JW
Adv Ther; 2020 May; 37(5):2303-2316. PubMed ID: 32297284
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in Brazil.
Pereira CAC; Baddini-Martinez JA; Baldi BG; Jezler SFO; Rubin AS; Alves RLR; Zonzin GA; Quaresma M; Trampisch M; Rabahi MF
J Bras Pneumol; 2019 Sep; 45(5):e20180414. PubMed ID: 31531619
[TBL] [Abstract][Full Text] [Related]
14. Subgroup Analysis for Chinese Patients Included in the INPULSIS
Xu Z; Li H; Wen F; Bai C; Chen P; Fan F; Hu N; Stowasser S; Kang J
Adv Ther; 2019 Mar; 36(3):621-631. PubMed ID: 30729456
[TBL] [Abstract][Full Text] [Related]
15. A retrospective study of the tolerability of nintedanib for severe idiopathic pulmonary fibrosis in the real world.
Nakamura M; Okamoto M; Fujimoto K; Ebata T; Tominaga M; Nouno T; Zaizen Y; Kaieda S; Tsuda T; Kawayama T; Hoshino T
Ann Transl Med; 2019 Jun; 7(12):262. PubMed ID: 31355229
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study.
Maher TM; Stowasser S; Nishioka Y; White ES; Cottin V; Noth I; Selman M; Rohr KB; Michael A; Ittrich C; Diefenbach C; Jenkins RG;
Lancet Respir Med; 2019 Sep; 7(9):771-779. PubMed ID: 31326319
[TBL] [Abstract][Full Text] [Related]
17. The tolerability and efficacy of antifibrotic therapy in patients with idiopathic pulmonary fibrosis: Results from a real-world study.
Zhao R; Xie B; Wang X; Zhang X; Ren Y; Wang C; Dai H
Pulm Pharmacol Ther; 2024 Mar; 84():102287. PubMed ID: 38242314
[TBL] [Abstract][Full Text] [Related]
18. South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).
Barratt SL; Mulholland S; Al Jbour K; Steer H; Gutsche M; Foley N; Srivastava R; Sharp C; Adamali HI
Front Pharmacol; 2018; 9():1480. PubMed ID: 30618768
[No Abstract] [Full Text] [Related]
19. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.
Crestani B; Huggins JT; Kaye M; Costabel U; Glaspole I; Ogura T; Song JW; Stansen W; Quaresma M; Stowasser S; Kreuter M
Lancet Respir Med; 2019 Jan; 7(1):60-68. PubMed ID: 30224318
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis.
Yoon HY; Park S; Kim DS; Song JW
Respir Res; 2018 Oct; 19(1):203. PubMed ID: 30340638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]